

**TRANSNASAL DELIVERABLES, INC.**  
**Pharmaceutical Delivery Systems**

**Executive Summary**

**CONTACT INFORMATION**

Terry Burka, CEO  
949-610-3345 /c  
tb@transnasal.com

Abraham Wien, Pres.  
395-609-9093 /c  
aw@transnasal.com  
2141 NW 1<sup>st</sup> Place  
Boca Raton, FL 33431

**EXECUTIVE TEAM**

Abraham Wien, Inventor/Pres.  
Terry Burka, MS/CEO  
Dr. Neil Ross, Pharm. D./CSO

**INDUSTRY**

Medical Devices  
Pharmaceutical Delivery Systems

**Financing Sought**

Round 1: \$4.22M (Seed, C-Notes)  
Round 2: \$8.69M (Early-stage)

**USE OF FUNDS**

R&D, Prototyping  
Trial Testing, Test Marketing  
FDA Applications and Patents  
Team Compensation  
Info-tech/MIS, Lab/Equipment  
Legal/Accounting/Insurance

**EMPLOYEES**

Executives, Administrative, Sales  
Yr. 1-5x; Yr. 2-5x  
Yr. 3-8x; Yr. 4-9x-11x

**ADVISORS/CONTRACTS**

██████████, MS Chem. Eng.  
██████████, Ph.D., D.Sc.  
██████████, MBA, CPA, CFA  
*Other:* 3-D Support; Mech. Eng.  
Bio. Eng.; Materials Eng.;  
Nanotech Eng.; Chem. Eng.

**ENTITY TYPE**

C-Corporation (expected)

**TECHNOLOGY: TRANSNASAL DELIVERABLES, INC. ("TDI")**

Visionary startup company having developed a patented nasal dilator ("ND") that improves breathing, reduces snoring and, while comfortably and securely resting on the nasal membranes, is capable of being specially engineered at its apex to deliver a variety of drugs to their targets in a controlled manner to improve health and wellbeing.

**MANAGEMENT AND ADVISORS**

TDI will be formed with 3 executives and 3 advisors. The Founder/President is a serial inventor and business executive with a career spanning 30 years in sustainable design, architecture, and real estate development. The CEO is expert in institutional real estate finance and investigative due diligence. The Chief Science Officer has over 30 years of pharmaceutical experience, including formulating drugs, setting up clinical trials, and collaborating with the U.S. FDA. Comprised of 2 science experts, TDI's advising board is complete. Mr. ██████████ founded ██████████ Pharmaceuticals and served as its *Principal Executive Officer and Chairman of the Board*. He manufactured and marketed advanced ██████████ drug delivery products achieving \$2B in sales. Dr. ██████████ is a world renowned expert in the field of biomaterials and medical devices, with over ██████████ U.S. patents. Dr. ██████████ was inducted in the *American Institute of Medical and Biological Engineering* and the *National Academy of Engineering*.

**COMPANY HISTORY**

The Company entity is not yet formed, and has no operating history.

**TECHNOLOGY/PROPRIETARY RIGHTS/SPECIAL KNOW HOW**

The Nasal Dilator technology is patented. The medical device known as the 'nasal dilator' will be engineered to deliver medicine. The science team has direct and specific experience with developing both, OTC and prescription-based drugs, and delivering them into the blood stream by penetrating tissue membranes.

**MARKETING AND SALES DISTRIBUTION CHANNELS**

Supply: At this writing, there are no FDA-approved transnasal devices with drug delivery capacity.

Demand: Millions of chronic sufferers, needing *instant* medication.

Absorption: Grocery, health and beauty chain stores, hospitals, physician offices, medical product companies, home health care, athletes, pharmacies.

Growth: Logarithmic potential as the U. S. FDA approves each specific drug and specifically drug-engineered tip design.

Pipeline: None known.

**COMPETITION**

Breathe Right Nasal Strips for the Nasal Dilator, and others. Pharmaceutical companies for the drug delivery components.

**Sources and Uses**

Sources: Series Seed: \$4.12M; Series A: \$8.93M.

Uses: R&D, U. S. FDA approvals, clinical trials, establishing supply chains, test marketing, retail channeling.

**Pro Forma Financial**

Summary Pro Forma Financial Statement	Yr. 1	Yr. 2	Yr. 3	Yr. 4	Yr. 5	Yr. 6	Yr. 7	Yr. 8	Yr. 9	Yr. 10
	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Net Operating Income (Loss)	(1,746,250)	(2,077,888)	(5,716,058)	(810,097)	29,911,777	52,960,482	91,479,237	138,526,632	260,315,667	503,040,726
Net Profit	(1,952,457)	(2,284,094)	(5,716,058)	(810,097)	22,252,149	31,776,289	54,887,542	83,115,979	156,189,400	301,824,436
CoGS plus Total OE	1,746,250	2,278,475	7,053,308	11,431,147	21,718,373	40,012,143	67,341,513	97,791,993	171,013,458	315,396,774
Accumulated Net Profit (Loss)	(1,952,457)	(4,236,551)	(9,952,609)	(10,762,706)	11,489,443	43,265,732	98,153,275	181,269,254	337,458,654	639,283,089
Retained Earnings (Accumulated Deficit)	(1,952,457)	(4,236,551)	(9,952,609)	(10,762,706)	11,489,443	23,265,732	78,153,275	161,269,254	317,458,654	619,283,089

**Notes to Summary Pro Forma Financial Statement**

1. PV at Series A: **\$710M**.
2. Terminal Value: **\$2.18B**; Periodic adjustments to the pro forma financial statements occur.
3. Series Seed/Convertible Note Holder 50.4X ROI. Series-A 36.7X ROI. (see Tenth Year Sale and Distribution; Caps apply)